In a report released yesterday, Glenn Novarro from RBC Capital reiterated a Buy rating on Transenterix Inc (TRXC), with a price target of $5. The company’s shares opened today at $2.87.
According to TipRanks.com, Novarro is a top 100 analyst with an average return of 13.6% and a 77.3% success rate. Novarro covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Baxter International, and Edwards Lifesciences.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Transenterix Inc with a $5 average price target, which is a 74.2% upside from current levels. In a report issued on November 9, Ladenburg also upgraded the stock to Buy with a $4.50 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $6.98 and a one-year low of $1.27. Currently, Transenterix Inc has an average volume of 6.39M.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TransEnterix, Inc. operates as a development stage medical device company. It focuses on research, development and sale of medical device robotics to improve minimally invasive surgery.
